AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22654449 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 2 L PEG solution
Number of subjects: 250
Study 22654449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride citrate (15 mg) with 2 L PEG solution (after excluding severe constipation)
Number of subjects: 250
Study 22654449 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 2 L PEG solution (after excluding severe constipation)
Number of subjects: 250
Study 22654449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride citrate (15 mg) with 2 L PEG solution (among previous colonoscopy experience subgroup)
Number of subjects: 250
Study 19397795 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of Blood Glucose (SMBG)
Number of subjects: 600
Study 19397795 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of Urine Glucose (SMUG)
Number of subjects: 600
Study 19397795 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study 17301734 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (10 mg)
Number of subjects: 20
Study 17301734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15103233 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin given after placenta delivery
Number of subjects: 51
Study 11311761 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir from 36 weeks of gestation to term (group 1)
Number of subjects: 489
Study 11311761 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 489
Study 11311761 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis with a history of genital herpes but no active episodes (group 3)
Number of subjects: 489
Study 10072236 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 14
Study 10072236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7543272 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal irradiation
Number of subjects: 0
Study 7543272 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemibody irradiation
Number of subjects: 0
Study 7543272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of strontium (89)
Number of subjects: 0
Study 7543272 — intervention group
Group type: COMPARATOR
Intervention: Single large treatments
Number of subjects: 0
Study 7543272 — intervention group
Group type: COMPARATOR
Intervention: Extended courses of treatment
Number of subjects: 0
Study 2250488 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical record audit with feedback
Number of subjects: 62
Study 2250488 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cancer screening reminders
Number of subjects: 62
Study 2250488 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 62
Study 7363739 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention program for high-risk infants
Number of subjects: 60
Study 7363739 — intervention group
Group type: COMPARATOR
Intervention: General population infants (control group)
Number of subjects: 60
Study 31829654 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshmen success intervention (9th grade leadership team, curriculum, peer navigators)
Number of subjects: 1588
Study 31829654 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshmen success intervention
Number of subjects: 1588
Study 31829654 — intervention group
Group type: COMPARATOR
Intervention: Control (business as usual)
Number of subjects: 1588
Study 30852235 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients (HFpEF)
Number of subjects: 108
Study 30852235 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients (HFpEF) with relevant baseline characteristics included
Number of subjects: 108
Study 30852235 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 108
Study 28017311 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb everolimus-eluting bioresorbable vascular scaffold (BVS)
Number of subjects: 754
Study 26026649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with higher ratings of the helpfulness of the PCPs' involvement
Number of subjects: 347
Study 26026649 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 347
Study 23246476 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 557
Study 23246476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557
Study 21693215 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg orally twice daily from day 0 to 7 postoperatively
Number of subjects: 74
Study 21693215 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 74
Study 19487934 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0
Study 19487934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17270674 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 716
Study 17270674 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 716
Study 17270674 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 716
Study 12603367 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic tension-type headache patients
Number of subjects: 16
Study 12603367 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 16
Study 10976543 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice daily)
Number of subjects: 10
Study 10976543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8974126 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented total parenteral nutrition (TPN)
Number of subjects: 0
Study 8974126 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented TPN
Number of subjects: 0
Study 8974126 — intervention group
Group type: COMPARATOR
Intervention: Control TPN
Number of subjects: 0
Study 1451930 — intervention group
Group type: EXPERIMENTAL
Intervention: sultamicillin 750 mg/day (n = 9)
Number of subjects: 110
Study 1451930 — intervention group
Group type: EXPERIMENTAL
Intervention: sultamicillin 1500 mg/day (n = 46)
Number of subjects: 110
Study 1451930 — intervention group
Group type: COMPARATOR
Intervention: cefuroxime axetil 500 mg/day (n = 51)
Number of subjects: 110
Study 1451930 — intervention group
Group type: COMPARATOR
Intervention: cefuroxime axetil 1000 mg/day (n = 4)
Number of subjects: 110
Study 6089581 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐adrenoceptor blocker propranolol (160 mg/day)
Number of subjects: 16
Study 6089581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3784283 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-out water immersion in Group 1 (N = 7)
Number of subjects: 15
Study 3784283 — intervention group
Group type: COMPARATOR
Intervention: Head-out water immersion in Group 2 (N = 8)
Number of subjects: 15
Study 29906310 — intervention group
Group type: EXPERIMENTAL
Intervention: Every-8-hour vancomycin dosing
Number of subjects: 20
Study 29906310 — intervention group
Group type: EXPERIMENTAL
Intervention: Every-8-hour cefepime dosing
Number of subjects: 20
Study 29906310 — intervention group
Group type: COMPARATOR
Intervention: Every-12-hour vancomycin dosing
Number of subjects: 20
Study 29906310 — intervention group
Group type: COMPARATOR
Intervention: Every-12-hour cefepime dosing
Number of subjects: 20
Study 26776557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PIIINP levels
Number of subjects: 74
Study 26776557 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ejection fraction
Number of subjects: 74
Study 26776557 — intervention group
Group type: EXPERIMENTAL
Intervention: PIIINP levels
Number of subjects: 74
Study 26776557 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels
Number of subjects: 74
Study 24837754 — intervention group
Group type: COMPARATOR
Intervention: Control group (Web-based smoking cessation intervention)
Number of subjects: 570
Study 22425637 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal rectus femoris transfer (DRFT)
Number of subjects: 32
Study 22425637 — intervention group
Group type: COMPARATOR
Intervention: NON‐DRFT
Number of subjects: 32
Study 19635945 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual (AV) modality
Number of subjects: 60
Study 19635945 — intervention group
Group type: COMPARATOR
Intervention: Audio-only (A-only) modality
Number of subjects: 60
Study 18428198 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel plus high-dose calcitriol
Number of subjects: 160
Study 18428198 — intervention group
Group type: COMPARATOR
Intervention: Weekly docetaxel
Number of subjects: 160
Study 16147846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular benzathine penicillin G suspension (Bicillin L‐A), 2.4 million units
Number of subjects: 53
Study 16147846 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 53
Study 14668176 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-task and dual-task complexity
Number of subjects: 0
Study 14668176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior wakefulness (< 40 h)
Number of subjects: 0
Study 10883741 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment groups
Number of subjects: 33
Study 10883741 — intervention group
Group type: COMPARATOR
Intervention: Placebo groups
Number of subjects: 33
Study 8836335 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Program (CP)
Number of subjects: 65
Study 8836335 — intervention group
Group type: COMPARATOR
Intervention: Reduced Program (RP)
Number of subjects: 65
Study 1308263 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol fat breakfast (527 mg cholesterol, 33 gm fat) for seven days in young females
Number of subjects: 10
Study 1308263 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol fat breakfast (527 mg cholesterol, 33 gm fat) for seven days in older females
Number of subjects: 10
Study 1308263 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol fat breakfast (527 mg cholesterol, 33 gm fat) for seven days in both age groups
Number of subjects: 10
Study 6730871 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (fentanyl + O2/N2O + postoperative pain relief with systemic opiates)
Number of subjects: 32
Study 6730871 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia + epidural analgesia (local anaesthetics + morphine) continued for 72 h
Number of subjects: 32
Study 6730871 — intervention group
Group type: COMPARATOR
Intervention: Non-operative control group
Number of subjects: 32
Study 31319319 — intervention group
Group type: EXPERIMENTAL
Intervention: UN Sustainable Development Goals (SDGs)
Number of subjects: 0
Study 31319319 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems approach to health and social justice
Number of subjects: 0
Study 31319319 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based approach for communication and engagement
Number of subjects: 0
Study 31319319 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions delivering health co-benefits
Number of subjects: 0
Study 30400959 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based distribution of OraQuick HIV Self Tests by trained lay distributors
Number of subjects: 0
Study 30400959 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV testing (SOC)
Number of subjects: 0
Study 30400959 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based distribution of OraQuick HIV Self Tests
Number of subjects: 0
Study 27313268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam 2000 mg/500 mg every 8 hours
Number of subjects: 1033
Study 27313268 — intervention group
Group type: COMPARATOR
Intervention: Doripenem 500 mg every 8 hours
Number of subjects: 1033
Study 24320690 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training for 8 weeks
Number of subjects: 23
Study 24320690 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 23
Study 22494399 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (60-min bout of cycle ergometry at 90% ventilatory threshold)
Number of subjects: 30
Study 22494399 — intervention group
Group type: COMPARATOR
Intervention: Control group (rested for 60 min)
Number of subjects: 30
Study 20566487 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 152
Study 20566487 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 152
Study 18398650 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavyweight double-filament polypropylene mesh (Prolene, 10 x 15 cm, group A, n = 60)
Number of subjects: 180
Study 18398650 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifilament heavyweight polypropylene mesh (Serapren, 10 x 15 cm, group B, n = 60)
Number of subjects: 180
Study 18398650 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite mesh (polyglactin and polypropylene, Vypro II, 10 x 15 cm, group C, n = 60)
Number of subjects: 180
Study 18398650 — intervention group
Group type: COMPARATOR
Intervention: Overall (all groups)
Number of subjects: 180
Study 15730434 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg) and herbal ephedra (20 mg ephedrine)
Number of subjects: 8
Study 15730434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 14642668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 0
Study 14642668 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 0
Study 14642668 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields
Number of subjects: 0
Study 14642668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 0
Study 14642668 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 0
Study 14642668 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock waves
Number of subjects: 0
Study 14642668 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Number of subjects: 0
Study 14642668 — intervention group
Group type: EXPERIMENTAL
Intervention: Short waves
Number of subjects: 0
Study 14642668 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwaves
Number of subjects: 0
Study 14642668 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrasound vibrations
Number of subjects: 0
Study 10908688 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic gel
Number of subjects: 184
Study 10908688 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam gel
Number of subjects: 184
Study 8621147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment
Number of subjects: 0
Study 1462402 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (n = 12, 240-360 mg)
Number of subjects: 24
Study 1462402 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (n = 12, 240-360 mg)
Number of subjects: 24
Study 3931216 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol 200 micrograms daily
Number of subjects: 119
Study 3931216 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol 800 micrograms daily
Number of subjects: 119
Study 3931216 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 1200 mg daily
Number of subjects: 119
Study 31654188 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 350
Study 30610771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic education
Number of subjects: 130
Study 30610771 — intervention group
Group type: COMPARATOR
Intervention: Usual diabetes education (Control)
Number of subjects: 130
Study 26364833 — intervention group
Group type: EXPERIMENTAL
Intervention: McDonald cerclage
Number of subjects: 90
Study 26364833 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxyprogesterone caproate (17OHP‐C)
Number of subjects: 90
Study 26364833 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 90
Study 24832974 — intervention group
Group type: EXPERIMENTAL
Intervention: CIVE
Number of subjects: 49
Study 24832974 — intervention group
Group type: EXPERIMENTAL
Intervention: VIVE
Number of subjects: 49
Study 24832974 — intervention group
Group type: EXPERIMENTAL
Intervention: CICE
Number of subjects: 49
Study 24832974 — intervention group
Group type: EXPERIMENTAL
Intervention: VICE
Number of subjects: 49
Study 24832974 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 49
Study 22652933 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity intervention
Number of subjects: 128
Study 20594468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 20
Study 20594468 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal saline)
Number of subjects: 20
Study 18325056 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin controlled-release 7.5 mg
Number of subjects: 1059
Study 18325056 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin controlled-release 15 mg
Number of subjects: 1059
Study 18325056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study 15983452 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (moderate sedation)
Number of subjects: 10
Study 15983452 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (deep sedation)
Number of subjects: 10
Study 15983452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12466781 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg) administered to patients showing signs of fatigue before reaching minimal HR (group A)
Number of subjects: 108
Study 12466781 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B) who spontaneously achieved minimal HR
Number of subjects: 108
Study 12466781 — intervention group
Group type: COMPARATOR
Intervention: Comparison of perfusion studies between group A and group B
Number of subjects: 108
Study 10728909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous etoposide 150 mg/M2
Number of subjects: 99
Study 10728909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous etoposide 150 mg/M2 with mannitol 15 gm/M2
Number of subjects: 99
Study 10728909 — intervention group
Group type: EXPERIMENTAL
Intervention: Low grade astrocytomas
Number of subjects: 99
Study 10728909 — intervention group
Group type: EXPERIMENTAL
Intervention: Medulloblastoma or PNET
Number of subjects: 99
Study 10728909 — intervention group
Group type: EXPERIMENTAL
Intervention: High grade astrocytomas
Number of subjects: 99
Study 10728909 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain stem gliomas
Number of subjects: 99
Study 7493659 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy foods group (n = 81) consuming approximately 30 grams of dairy protein daily
Number of subjects: 158
Study 7493659 — intervention group
Group type: COMPARATOR
Intervention: Dairy-free diet group (n = 77) eating no dairy foods
Number of subjects: 158
Study 2268021 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with fentanyl 50 micrograms
Number of subjects: 100
Study 2268021 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with fentanyl 100 micrograms
Number of subjects: 100
Study 2268021 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% plain
Number of subjects: 100
Study 2268021 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% with fentanyl 50 micrograms
Number of subjects: 100
Study 2268021 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% with fentanyl 100 micrograms
Number of subjects: 100
Study 2268021 — intervention group
Group type: COMPARATOR
Intervention: Overall
Number of subjects: 100
Study 6787694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pirenzepine 10 mg
Number of subjects: 0
Study 6787694 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 0
Study 30739210 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D image group
Number of subjects: 71
Study 30739210 — intervention group
Group type: COMPARATOR
Intervention: two‐dimensional computed tomography (CT) group
Number of subjects: 71
Study 28931011 — intervention group
Group type: EXPERIMENTAL
Intervention: Central information highlighting flaws in the expert’s message (e.g., quality of the research presented by the expert)
Number of subjects: 0
Study 28931011 — intervention group
Group type: COMPARATOR
Intervention: Peripheral information about the expert (e.g., credentials)
Number of subjects: 0
Study 25400242 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine care
Number of subjects: 101
Study 25400242 — intervention group
Group type: COMPARATOR
Intervention: Traditional outpatient visits (Control)
Number of subjects: 101
Study 22429008 — intervention group
Group type: EXPERIMENTAL
Intervention: Corega Extradent for 5 min
Number of subjects: 35
Study 22429008 — intervention group
Group type: EXPERIMENTAL
Intervention: Corega Extradent for 8 h
Number of subjects: 35
Study 22429008 — intervention group
Group type: EXPERIMENTAL
Intervention: NitrAdine™ Seniors for 15 min
Number of subjects: 35
Study 22429008 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl 5.25%
Number of subjects: 35
Study 22429008 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 35
Study 21601480 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 138
Study 21601480 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 138
Study 18655272 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 108
Study 18655272 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 108
Study 18655272 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia
Number of subjects: 108
Study 17031011 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis (BB‐12)
Number of subjects: 59
Study 17031011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (ATCC 55730)
Number of subjects: 59
Study 17031011 — intervention group
Group type: COMPARATOR
Intervention: Probiotics-free formula
Number of subjects: 59